Skip to main
AQST

AQST Stock Forecast & Price Target

AQST Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aquestive Therapeutics Inc is poised for positive growth due to its strong positioning in the no-needle epinephrine market, enhanced by the opportunity for both oral and intranasal alternatives. The FDA's recent decision not to require an Advisory Committee meeting for the NDA of Anaphylm has led to a significant 43.77% increase in shares, reflecting investor confidence in the company's product pipeline. Furthermore, the successful submission of a comprehensive data package addressing key regulatory topics suggests a favorable trajectory for potential approval and market expansion.

Bears say

Aquestive Therapeutics faces several fundamental issues contributing to a negative outlook on its stock. The company is at risk of unsuccessful development of its pipeline product AQST-109, coupled with potential revenue erosion from its licensed commercial products, which could adversely affect its financial performance. Additionally, the need for capital raise to strengthen the balance sheet raises concerns about its liquidity and long-term viability in a competitive market.

AQST has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aquestive Therapeutics Inc (AQST) Forecast

Analysts have given AQST a Buy based on their latest research and market trends.

According to 5 analysts, AQST has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aquestive Therapeutics Inc (AQST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.